Cibus and Crystal Crop partner to gene-edit India's mustard crop
Cibus (Nasdaq: CBUS) and India's Crystal Crop Protection have signed an agreement to develop gene-edited traits in Brassica juncea, the mustard variety that dominates Indian oilseed farming. Under the terms, Crystal Crop takes an exclusive licence to evaluate and commercialise the resulting traits in India, while Cibus contributes its precision gene-editing platform to develop the improvements.
Mustard occupies roughly 8.5 million hectares across India, yet the country still imports more than half of its edible oil consumption, around 17 million tonnes annually. Average Indian mustard yields sit at 1,200 to 1,400 kilograms per hectare, well below the 1,800 to 2,000 kilograms typical in leading producing nations. Conventional breeding has made limited progress on that gap over decades, which is the problem Cibus's platform is designed to address.
The technology and the deal
Cibus applies targeted edits to a crop plant's own genome, introducing no foreign DNA. That distinction carries regulatory weight in India: in 2022, the country's environment ministry ruled that gene-edited crops without foreign DNA additions fall outside its framework for genetically modified organisms, clearing a path to field deployment that would otherwise require years of additional regulatory process.
Crystal Crop brings its established mustard breeding programme, deep knowledge of the Indian seed market, and a distribution network of more than 14,800 independent partners across 23 states and four union territories. The combination is intended to move improved seed from laboratory to farm at a scale that asset-light technology licensors struggle to achieve alone.
Peter Beetham, co-founder, President and Chief Operating Officer of Cibus, said the partnership draws on the company's 25 years of experience making "precise improvements to a plant's own genes" and on Crystal Crop's direct relationships with Indian growers.
Regulatory and policy context
The agreement aligns with India's National Mission on Edible Oils and Oilseeds, launched in 2024, which targets an increase in national oilseed production from around 39 million tonnes in 2022-23 to approximately 70 million tonnes by 2030-31. The mission explicitly names genome editing as one of the tools to reach that goal, giving the Cibus-Crystal Crop programme a degree of policy tailwind that commercial gene-editing deals in some other markets lack.
Crystal Crop's own profile is also in transition. The company filed a draft red herring prospectus with India's SEBI in December 2025 for a proposed IPO, and in May 2026 it agreed to acquire FMC Corporation's India crop protection business. Absorbing those two structural changes while advancing a novel biotech partnership adds execution complexity that investors will monitor.
For Cibus, the deal extends a licensing model the company has been building across regional seed and crop businesses globally. The company describes itself as a trait developer rather than a seed company, earning royalties when partners commercialise improved varieties. That royalty-on-commercialisation structure means near-term revenue recognition from the Crystal Crop agreement is likely to lag development timelines significantly.
The broader gene-editing-in-agriculture space has attracted sustained investment and regulatory attention across Asia. Japan's MHLW and MAFF have published gene-editing food frameworks, and China has moved to approve several genome-edited crop varieties domestically, signalling that the Indo-Pacific region may become a key proving ground for regulatory acceptance of these technologies ahead of markets in the EU, where the political debate around new genomic techniques legislation remains unresolved.